Campbell & Co Investment Adviser’s ChemoCentryx, Inc. CCXI Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-17,827	Closed	-$447K	–	991
2022 Q1	$447K	Sell	17,827 -14,723	-45%	-$414K	0.12%	317
2021 Q4	$1.19M	Buy	+32,550	New	+$1.14M	0.41%	37
2021 Q1	–	Sell	-5,059	Closed	-$313K	–	645
2020 Q4	$313K	Sell	5,059 -3,500	-41%	-$200K	0.19%	217
2020 Q3	$469K	Buy	8,559 +299	+4%	+$16.1K	0.35%	84
2020 Q2	$475K	Buy	+8,260	New	+$450K	0.6%	26

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Campbell & Co Investment Adviser's CCXI Position: Q2 2022 in Review

Campbell & Co Investment Adviser sold out of ChemoCentryx, Inc. (CCXI) in Q2 2022, closing a stake of 17,827 shares — an estimated $447K sold.

Campbell & Co Investment Adviser first reported a position in CCXI in Q2 2020 and held it in 5 quarters. The position peaked at $1.19M in Q4 2021. 182 funds tracked by Wall St. Rank hold CCXI as of Q2 2022.

Campbell & Co Investment Adviser reported no remaining ChemoCentryx, Inc. position as of Q2 2022 after selling out during the quarter.
Campbell & Co Investment Adviser sold 17,827 ChemoCentryx, Inc. shares in Q2 2022, an estimated $447K.
Campbell & Co Investment Adviser first reported a position in ChemoCentryx, Inc. in Q2 2020 and held it in 5 quarters.
Campbell & Co Investment Adviser's ChemoCentryx, Inc. position peaked at $1.19M in Q4 2021.
182 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2022.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2022, filed 9 Aug 2022.